Lenvatinib
Lenvatinib is a multiple receptor tyrosine kinase inhibitor. It inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4)
Enzalutamide
Enzalutamide is a nonsteroidal antiandrogen. it is a potent androgen receptor signalling inhibitor that blocks several steps in the androgen receptor signalling pathway and competitively inhibits androgen binding to androgen receptors
Crizotinib
Crizotinib is a multi receptor tyrosine kinase (RTK) inhibitor. It inhibits the receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), ROS1 (c-ros), and Recepteur d’Origine Nantais (RON)
Osimertinib
Osimertinib is a tyrosine kinase inhibitor. It is a kinase inhibitor of the epidermal growth factor receptor (EGFR), which binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion)
Vandetanib
Vandetanib is a multikinase inhibitor. It inhibits tyrosine kinases including epidermal growth factor reception (EGFR), vascular endothelial growth factor (VEGF), rearranged during transfection (RET), protein tyrosine kinase 6 (BRK), TIE2, EPH
Pomalidomide
Pomalidomide is an immunomodulatory agent with antineoplastic activity. It inhibits proliferation and induced apoptosis of hematopoietic tumor cells
